Infinimmune Announces Research Collaboration with Immunome
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced a research collaboration agreement with Immunome, Inc. (NASDAQ: IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed.Infinimmune rapidly optimizes and engineers early leads into high-fidelity, development-ready therapeutic candidates using its GLIMPSE™ and Anthrobody® platforms.“Infinimmune expects this collaboration to demonstrate how our GLIMPSE™ platform can optimize and enhance existing antibodies with unprecedented speed,” said Wyatt McDonnell, CEO & Co-Founder, Infinimmune. “As GLIMPSE was trained on our proprietary human antibody data, we’re able to systematically improve key properties like affinity, stability, and developability while maintaining the human-like characteristics that are critical for therapeutic succes
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Immunome (NASDAQ:IMNM) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $36.00 price target on the stock.MarketBeat
- Immunome to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Immunome to Present at Upcoming Investor ConferencesBusiness Wire
- Immunome (NASDAQ:IMNM) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 11/7/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- IMNM's page on the SEC website